

*** The editor has said, "Please correct the mismatches found between the labeling of supplementary figures and the legends." It is unclear what mismatches there are below... please clarify.

Formatted: Font: Palatino Linotype, 10 pt

Appendix

Figure S1




Figure S1. Representative flow cytometry gating strategies

A) PD-L1 expression on BrCa cell lines. Representative plot from MDA MB 468.

B) Quantification of CD4⁺/CD8⁺ splenocytes from the *in vivo* EMT6 study. Representative plot shown.

Figure S2

A




Figure S2. Representative diagram of the *in vivo* experimental protocol

A) Four groups of 12-week old BALB/c mice (Charles River) were implanted on day 0 with 2×10^5 EMT6 cells subcutaneously (s.c) into the right mammary pad (N=15/group). Once tumors were palpable (approximately day 6), therapy was initiated. Mice were grouped into cohorts and treated with i.p PBS, intratumoral live RV (5×10^8 PFU), anti-PD-1 antibody (RMP1-14, BioXcell, Connecticut, USA)(0.2 mg i.p.), or a combination of these agents.

Figure S3




Figure S3. Representative flow cytometry gating strategies

A) Quantification of memory CD4⁺/CD8⁺ T cells (TEM, TCM) from the *in vivo* EMT6 study. Representative plot shown.

B) Quantification of Treg (CD4⁺ CD25⁺ FOXP3⁺) from *in vivo* EMT6 study. Representative plot shown.

Figure S4




Figure S4. Representative flow cytometry gating strategies

A) Quantification of intracellular cytokine production from CD4⁺/CD8⁺ splenocytes from the *in vivo* EMT6 study. Representative plot of IFN γ shown.